Radha Krishna Vegunta, MD
Hematology & Oncology · Fargo, NDNPI 1750669214
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,193 of the $36,991 with a category attached, or 81.6%. 17 manufacturers reported payments, led by AstraZeneca at 51.5% of the total. Reporting peaked in 2022 at $9,663 and has fallen 67.6% since, to $3,131 in 2025. Among hematology & oncology clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $606.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Gilead$7K
- Puma Biotechnology, Inc.$2K
- Exelixis Inc.$1K
- Incyte Corporation$1K
- Johnson & Johnson$1K
- plus $5K from 11 others
Across 2 payments — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
What the payments were for
- Consulting fees$30,19382%
- Speaking & faculty fees$1,6705%
- Travel & lodging$3,92311%
- Food & beverage$1,1673%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $19,052 |
| Gilead(2 entities) | 13 | $6,751 |
| Puma Biotechnology, Inc. | 1 | $1,800 |
| Exelixis Inc. | 1 | $1,470 |
| Incyte Corporation | 1 | $1,440 |
| Johnson & Johnson | 2 | $1,405 |
| Eisai Inc. | 3 | $1,189 |
| Merck | 8 | $1,159 |
| Bayer | 1 | $900 |
| Beigene USA, Inc. | 1 | $675 |
| Janssen Scientific Affairs, LLC | 2 | $300 |
| Cardinal Health 110 LLC | 1 | $275 |
| Sobi, Inc | 1 | $200 |
| Daiichi Sankyo Inc. | 1 | $200 |
| Sirtex Medical Inc | 1 | $86 |
| Progenics Pharmaceuticals, Inc. | 1 | $64 |
| Pfizer | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,991 in reported general payments places this provider in the 95th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 13 | $329,489 |
| TagrissoOsimertinib Mesylate | 12 | $206,461 |
| VerzenioAbemaciclib | 14 | $205,582 |
| BrukinsaZanubrutinib | 14 | $202,727 |
| EliquisApixaban | 51 | $30,898 |
| Abiraterone Acetate | 129 | $30,167 |
| XareltoRivaroxaban | 24 | $19,150 |
| Anastrozole | 118 | $2,497 |
| Tamoxifen Citrate | 55 | $1,798 |
| Potassium Chloride | 55 | $1,158 |
| Letrozole | 49 | $1,117 |
| Prednisone | 171 | $1,094 |
| Hydroxyurea | 46 | $1,021 |
| Ondansetron Hcl | 64 | $759 |
| Oxycodone Hcl | 46 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $1,470 | $329,48913 claims |
| AstraZenecaTagrisso | $19,052 | $206,46112 claims |
| Beigene USA, Inc.Brukinsa | $675 | $202,72714 claims |
| PfizerEliquis | $26 | $30,89851 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $300 | $30,167129 claims |
| Johnson & JohnsonXarelto | $1,405 | $19,15024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 hematology & oncology providers in North Dakota.
Other hematology & oncology in Fargo
- Mahendra GuptaFargo$96K
- Harish AhujaFargo$26K
- Michael DurandoFargo$2K
- Daniel AlmquistFargo$620
- Jeffrey WiisanenFargo$444
- Richard SheppardFargo$410
- Julia ParrishFargo$401
- Anu GabaFargo$366
- Howard RussellFargo$254
- Gerald GrossFargo$173
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.